Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer
Abstract Therapeutic anti-PD-L1 antibodies are safe as a monotherapy, albeit with minimal efficacy in triple-negative breast cancer (TNBC). This trial aimed to test the safety and efficacy of Durvalumab and Paclitaxel in metastatic TNBC. In this open-label, one-arm trial, five cycles of weekly pacli...
Guardado en:
Autores principales: | Hazem Ghebeh, Adher Al-Sayed, Riham Eiada, Leilani Cabangon, Dahish Ajarim, Kausar Suleman, Asma Tulbah, Taher Al-Tweigeri |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4082da344ce44ce6b8b8a7859e11152b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women.
por: Dilek Colak, et al.
Publicado: (2013) -
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Julia Foldi, et al.
Publicado: (2021) -
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick O, et al.
Publicado: (2021) -
Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience
por: Vrankar Martina, et al.
Publicado: (2021) -
Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
por: Mary H. Young, et al.
Publicado: (2021)